Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126751441 | 12675144 | 1 | I | 201503 | 20150505 | 20160823 | 20160823 | EXP | CA-AMGEN-CANSL2015044183 | AMGEN | 55.00 | YR | A | F | Y | 0.00000 | 20160823 | CN | CA | CA |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126751441 | 12675144 | 1 | PS | ENBREL | ETANERCEPT | 1 | Unknown | 50 MG, UNK | U | 103795 | 50 | MG | SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE | ||||||
| 126751441 | 12675144 | 2 | SS | ACTEMRA | TOCILIZUMAB | 1 | Unknown | UNK | 0 | ||||||||||
| 126751441 | 12675144 | 3 | SS | ARAVA | LEFLUNOMIDE | 1 | Unknown | UNK | 0 | TABLET | |||||||||
| 126751441 | 12675144 | 4 | SS | CIMZIA | CERTOLIZUMAB PEGOL | 1 | Subcutaneous | UNK | 0 | ||||||||||
| 126751441 | 12675144 | 5 | SS | HUMIRA | ADALIMUMAB | 1 | Subcutaneous | UNK | 0 | ||||||||||
| 126751441 | 12675144 | 6 | SS | LEFLUNOMIDE. | LEFLUNOMIDE | 1 | Unknown | UNK | 0 | TABLET | |||||||||
| 126751441 | 12675144 | 7 | SS | METHOTREXATE. | METHOTREXATE | 1 | Unknown | UNK | 0 | ||||||||||
| 126751441 | 12675144 | 8 | SS | PLAQUENIL | HYDROXYCHLOROQUINE SULFATE | 1 | Unknown | UNK | 0 | TABLET | |||||||||
| 126751441 | 12675144 | 9 | SS | SULFASALAZINE. | SULFASALAZINE | 1 | Unknown | 0 | |||||||||||
| 126751441 | 12675144 | 10 | SS | XELJANZ | TOFACITINIB CITRATE | 1 | Oral | 5 MG, BID | 0 | 5 | MG | BID | |||||||
| 126751441 | 12675144 | 11 | C | ASPIRIN. | ASPIRIN | 1 | UNK | 0 | |||||||||||
| 126751441 | 12675144 | 12 | C | CYMBALTA | DULOXETINE HYDROCHLORIDE | 1 | UNK | 0 | |||||||||||
| 126751441 | 12675144 | 13 | C | HYDROMORPHONE | HYDROMORPHONE | 1 | UNK | 0 | |||||||||||
| 126751441 | 12675144 | 14 | C | ORENCIA | ABATACEPT | 1 | UNK | 0 | |||||||||||
| 126751441 | 12675144 | 15 | C | SIMPONI | GOLIMUMAB | 1 | Subcutaneous | UNK | 0 | ||||||||||
| 126751441 | 12675144 | 16 | C | SYNTHROID | LEVOTHYROXINE SODIUM | 1 | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126751441 | 12675144 | 1 | Rheumatoid arthritis |
| 126751441 | 12675144 | 2 | Product used for unknown indication |
| 126751441 | 12675144 | 3 | Product used for unknown indication |
| 126751441 | 12675144 | 4 | Rheumatoid arthritis |
| 126751441 | 12675144 | 5 | Rheumatoid arthritis |
| 126751441 | 12675144 | 6 | Rheumatoid arthritis |
| 126751441 | 12675144 | 7 | Rheumatoid arthritis |
| 126751441 | 12675144 | 8 | Rheumatoid arthritis |
| 126751441 | 12675144 | 9 | Rheumatoid arthritis |
| 126751441 | 12675144 | 10 | Rheumatoid arthritis |
| 126751441 | 12675144 | 15 | Rheumatoid arthritis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126751441 | 12675144 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126751441 | 12675144 | Adverse event | |
| 126751441 | 12675144 | Drug ineffective | |
| 126751441 | 12675144 | Drug intolerance | |
| 126751441 | 12675144 | Extremity contracture | |
| 126751441 | 12675144 | Psoriasis | |
| 126751441 | 12675144 | Pustular psoriasis | |
| 126751441 | 12675144 | Rheumatoid arthritis | |
| 126751441 | 12675144 | Scar |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126751441 | 12675144 | 1 | 20140822 | 0 | ||
| 126751441 | 12675144 | 10 | 20160105 | 0 |